Top Fully Remote Biotech Companies (41)
Don't see your company?
Create a company profile
Avadel (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. At Avadel, our core values foster an atmosphere of innovation and collaboration. In everything we do, we consider the patient experience, listening to their needs as we pursue the development and delivery of medicines that will transform the treatment landscape and have the greatest impact on people living with narcolepsy. Learn more about us at www.avadel.com and follow us on Twitter at @AvadelPharma.
Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders
Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology. For more information, visit scorpiontx.com.
Altos Labs™ is a biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine. The company comprises a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission. Altos has operations in the San Francisco Bay Area and San Diego, and in Cambridge, UK, with significant collaborations in Japan. Note: Altos Labs will not ask you to download a messaging app for an interview or outlay your own money to get started as an employee. If this sounds like your interaction with people claiming to be with Altos, it is not legitimate and has nothing to do with Altos.
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.
Please note that this company page is no longer updated. Meet us at https://www.linkedin.com/company/bio-rad-antibodies. As of May 17 2016, AbD Serotec, a Bio-Rad company changed its name to Bio-Rad. Following this re-branding, we created a new LinkedIn showcase page that features all the latest news, updates and useful resources from the antibody team at Bio-Rad. Please follow us on this new page (https://www.linkedin.com/company/bio-rad-antibodies) to keep in touch with us on LinkedIn.
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible. We’re building a first-in-kind platform designed to sit at the intersection of RNA technology delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, protein replacement and regenerative medicine. Founded by experts in the fields of genetic medicine and RNA development and delivery, we have a dynamic operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers and business leaders.
At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine.
Parachute is a new kind of plasma donation company that allows individuals to earn money while creating life-saving medicine. Plasma is used to create medicine that treats chronic illnesses, including immune disorders, liver disease, bleeding disorders, and cancer. Right now, there’s a severe plasma shortage, which is impacting patients’ access to these life-saving treatments
Hi Fidelity Genetics is a computational biology company aiming to change the productivity of global agriculture
BioNews is a health media company focused on rare diseases and rare patient experiences. BioNews provides an insider’s view into disease and treatment news, condition management information, and community across more than 60+ diseases and brands. A fierce champion of the rare voice, BioNews brands are designed to reach, engage, and elevate even the smallest patient populations. We’re the only rare news and information property in the U.S. and are committed to the insider’s view into a rare disease or experience. People turn to our brands for timely treatment news, management, and community.
Pardes is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. By capitalizing on emerging patient-friendly innovations from telehealth to new at-home diagnostic tools, Pardes is cultivating and harvesting the fruits of systemic change. We are on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
The Public Health Company (PHC Global) is developing the first global biosecurity platform to provide enterprises a SaaS-enabled service for the management of bio-risks. PHC combines world-class expertise with cutting edge technology to be the global solution to enterprise risk management. PHC focuses on intersecting physical world threats across diverse use-cases to deliver actionable and predictive intelligence that enables dynamic risk management with unprecedented speed and scale
° Mycelium production Mycelia produces and commercializes mycelium. From our large collection of strains, we produce mother cultures, mother spawn and spawn which are sold all over the world. °Mycelia School Our long standing experience and solid scientific basis in mycelium production, enabled us to create the Mycelia School. We offer trainings on spawn production, sterilised substrate and lignicolous mushroom production and lab design. °R&D We are also involved in a number of R&D activities in view of constant improvement of its production. Our main R&D focus is the development of new species and maintenance of existing species in a structural research basis.
Protalix (NYSE, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Calibre Scientific is a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. The Company is committed to pushing the boundaries of science and innovation through internal expertise combined with strategic acquisitions that help deliver a differentiated and comprehensive set of products, services and support to our customers. Calibre Scientific was founded in 2016 by assembling a portfolio of niche life science companies, across various key verticals, that have an unrivaled ability to address the unique challenges of their respective markets. Through a combination of acquisitions and organic growth, our global reach extends into over 175 countries, empowering customers all over the world. Headquartered in Holland, Ohio, Calibre Scientific continues to grow across a wide array of verticals and geographies, further diversifying its product offering and global footprint to laboratories around the world.
Trialwise is a woman-owned, boutique clinical research organization (CRO) specializing in early phase clinical studies and niche consulting. We intentionally partner with a limited number of biotech and pharma clients to offer a customized approach to managing projects efficiently without compromising quality, accuracy, or adherence to protocol and regulatory compliance. Since our inception, Trialwise has operated as a decentralized team working cross-functionally in an environment unencumbered by silos and bureaucracy. Our collaborative approach with our clients ensures we deliver the quality, personal attention, and cost efficiencies on which Trialwise has built its reputation. Trialwise president, Beth Brinsdon, founded the company in 1999 after two decades in the pharmaceutical industry. She observed that start-up and small-to-midsize biotech companies in the early stages of drug development require a high level of personalized service, a level that can be best provided by a small CRO. In 2015, she renamed the company to Trialwise and began scaling operations with a remote team to collaborate with select clients ranging from start-ups to established bio-pharma companies. The Trialwise approach is attentive, flexible, proactive, and committed to the highest quality industry standards in the following areas: - Protocol Development - Site Qualification - Risk Identification and Assessment - Study Start-up - Database Development and Management - Risk-based Management - Traditional Monitoring - Statistical Programming of CDISC Compliant Datasets - Statistical Analysis - Quality Assurance Oversight - Clinical Study Report Development - Document Processing and eCTD Compliant Granular ePub - Clinical Trial Registration and Results Disclosure - Staffing Support
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a highly selective, oral KIT inhibitor for treatment of dermal, respiratory and gastrointestinal inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with mast-cell mediated inflammatory diseases. By inhibiting KIT, we believe we can provide broad symptomatic relief to patients with a range of disorders, including chronic spontaneous urticaria and severe asthma
NanoBiotech Pharma, Inc is a healthcare company that focuses & deals with the reversal of cardiovascular issues occurring in midlife to aged people.
Work Your Passion. Live Your Purpose.
